A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...
ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...
A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback